Vaccines Production Sanofi Aventis Invests US $ 300 Millions in Indian Subsidiary

Editor: Dominik Stephan

Sanofi Aventis boost its subsidiary Shanta Biotechnics with investments of US $ 300 millions. With this money, the Indian company shall produce vaccines for the global markets.

Related Companies

(Picture: Sanofi)
(Picture: Sanofi)

Hyderabad/India – According to the Indian Economic Times Sanofi Aventis plans a US $ 300 millions investment in its subsidiary Shantra Biotechnics, a company bought by the French based multinational in 2009 for US $ 500 millions. With this investments, Shanta shall be able to produce vaccines for the global market, insiders say. This announcement marks only the latest step of Sanofi Aventis current strategy to boost its position in emerging markets such as India and China with further investments. Especially vaccines, animal health and consumer health products are estimated to provide sustainable profit growth in the post-blockbuster era, officials said.